Innate Pharma (IPHA) Equity Average (2018 - 2019)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Innate Pharma (IPHA) has disclosed Equity Average for 2 consecutive years, with $215.8 million as the latest value for Q4 2019.

• For the quarter ending Q4 2019, Equity Average rose 47.74% year-over-year to $215.8 million, compared with a TTM value of $215.8 million through Dec 2019, up 47.74%, and an annual FY2019 reading of $220.5 million, up 49.69% over the prior year.
• Equity Average was $215.8 million for Q4 2019 at Innate Pharma, up from $146.0 million in the prior quarter.
• Across five years, Equity Average topped out at $215.8 million in Q4 2019 and bottomed at $146.0 million in Q4 2018.

Peer Comparison